Making trials matter: pragmatic and explanatory trials and the problem of applicability
TLDR
If the authors want evidence from trials to be used in clinical practice and policy, trialists should make every effort to make their trial widely applicable, which means that more trials should be pragmatic in attitude.Abstract:
Randomised controlled trials are the best research design for decisions about the effect of different interventions but randomisation does not, of itself, promote the applicability of a trial's results to situations other than the precise one in which the trial was done. While methodologists and trialists have rightly paid great attention to internal validity, much less has been given to applicability. This narrative review is aimed at those planning to conduct trials, and those aiming to use the information in them. It is intended to help the former group make their trials more widely useful and to help the latter group make more informed decisions about the wider use of existing trials. We review the differences between the design of most randomised trials (which have an explanatory attitude) and the design of trials more able to inform decision making (which have a pragmatic attitude) and discuss approaches used to assert applicability of trial results. If we want evidence from trials to be used in clinical practice and policy, trialists should make every effort to make their trial widely applicable, which means that more trials should be pragmatic in attitude.read more
Citations
More filters
Journal ArticleDOI
The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon,Shaun Treweek,Frank Sullivan,Peter T. Donnan,Kevin E. Thorpe,Merrick Zwarenstein +5 more
TL;DR: Advice is given on how to use an improved, validated version of PRECIS, which has been developed with the help of over 80 international trialists, clinicians, and policymakers, to support the explicit matching of design decisions to how the trial results are intended to be used.
Journal ArticleDOI
Midwifery and quality care: findings from a new evidence-informed framework for maternal and newborn care
Mary J. Renfrew,Alison McFadden,Maria Helena Bastos,James Campbell,Andrew Amos Channon,Ngai Fen Cheung,Deborah Rachel Audebert Delage Silva,Soo Downe,Holly Powell Kennedy,Address Malata,Felicia McCormick,Laura Wick,Eugene Declercq +12 more
TL;DR: A system-level shift from maternal and newborn care focused on identification and treatment of pathology for the minority to skilled care for all is supported, which includes preventive and supportive care that works to strengthen women's capabilities in the context of respectful relationships.
Journal ArticleDOI
A pragmatic view on pragmatic trials
TL;DR: This review describes the concept of pragmatism, and explains in particular that there is a continuum between pragmatic and explanatory trials, rather than a dichotomy.
Journal ArticleDOI
A primer on effectiveness and efficacy trials.
TL;DR: This primer highlights several differences between efficacy and effectiveness studies including study design, patient populations, intervention design, data analysis, and result reporting.
Journal ArticleDOI
Early palliative care for adults with advanced cancer
Markus W. Haun,Stephanie Estel,Gerta Rücker,Hans-Christoph Friederich,Matthias Villalobos,Michael Thomas,Mechthild Hartmann +6 more
TL;DR: Compared with usual/standard cancer care alone, early palliative care significantly improved health-related quality of life at a small effect size, and survival among adults with a diagnosis of advanced cancer.
References
More filters
Journal ArticleDOI
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
James C. Grotta,M Kothari,K.M.A. Welch,Joseph P. Broderick,Barbara C. Tilley,Thomas G. Brott,Marler,Patrick D. Lyden,Paul M. O'Byrne +8 more
Journal ArticleDOI
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
Barnett Hjm.,D W Taylor,Richard Haynes,David L. Sackett,Sydney J. Peerless,Gary G. Ferguson,Allan J. Fox,R N Rankin,Vladimir Hachinski,Wiebers Do,Michael Eliasziw +10 more
TL;DR: Carotid endarterectomy is highly beneficial to patients with recent hemispheric and retinal transient ischemic attacks or nondisabling strokes and ipsilateral high-grade stenosis of the internal carotid artery.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Book
Users' Guides to the Medical Literature
Gordon H. Guyatt,Drummond Rennie +1 more
TL;DR: Without a way of critically appraising the information they receive, clinicians are relatively helpless in deciding what new information to learn and decide how to modify their practice.
Journal ArticleDOI
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Robert S. Bresalier,Robert S. Sandler,Hui Quan,James A. Bolognese,Bettina Oxenius,Kevin J. Horgan,Christopher Lines,Robert H. Riddell,Dion Morton,Angel Lanas,Marvin A. Konstam,John A. Baron +11 more
TL;DR: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.